Belumosudil FDA Approval Status
FDA Approved: No
Generic name: belumosudil
Company: Kadmon Holdings, Inc.
Treatment for: Graft-versus-host disease
Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) in development for the treatment of patients with chronic graft-versus-host disease (cGVHD).
Development Timeline for belumosudil
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.